[An evaluation of the clinical usefulness of amifostine (YM-08310), radioprotective agent. A double-blind placebo-controlled study. 2. Abdominal and pelvic tumors].
D000328:Adult; D000368:Aged; D004999:Amifostine / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000532:radiotherapy; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009946:Organothiophosphorus Compounds / Q000627:therapeutic use*; D010051:Ovarian Neoplasms / Q000532:radiotherapy; D010386:Pelvic Neoplasms / Q000532:radiotherapy*; D011837:Radiation-Protective Agents / Q000627:therapeutic use*; D002583:Uterine Cervical Neoplasms / Q000532:radiotherapy*
D009946:Organothiophosphorus Compounds; D011837:Radiation-Protective Agents; D004999:Amifostine